AIM IMMUNOTECH INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.362 USD | -0.28% |
|
-5.97% | -17.71% |
| May. 16 | Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024 | |
| May. 15 | AIM ImmunoTech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 4.496 | 72.83 | 44.02 | 15 | 21.49 | 18.56 | - | - |
| Enterprise Value (EV) 1 | 4.496 | 72.83 | 44.02 | 15 | 21.49 | 18.56 | 18.56 | 18.56 |
| P/E ratio | -0.21 x | -3.98 x | -2.3 x | -0.78 x | -0.73 x | -0.82 x | -0.8 x | -0.66 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 32.1 x | 447 x | 326 x | 106 x | 106 x | 108 x | 10.4 x | 4.86 x |
| EV / Revenue | 32.1 x | 447 x | 326 x | 106 x | 106 x | 108 x | 10.4 x | 4.86 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | 0.44 x | 1.23 x | 0.78 x | 0.39 x | - | -1.65 x | -0.56 x | - |
| Nbr of stocks (in thousands) | 8,264 | 40,686 | 47,849 | 48,082 | 48,842 | 51,281 | - | - |
| Reference price 2 | 0.5440 | 1.790 | 0.9200 | 0.3119 | 0.4399 | 0.3620 | 0.3620 | 0.3620 |
| Announcement Date | 3/30/20 | 3/31/21 | 3/31/22 | 3/31/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.14 | 0.163 | 0.135 | 0.141 | 0.202 | 0.1725 | 1.78 | 3.82 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -12.44 | -15.02 | -17.06 | -19.92 | -31.92 | -23.86 | -26.93 | -33.77 |
| Operating Margin | -8,887.86% | -9,212.88% | -12,636.3% | -14,129.79% | -15,800% | -13,834.49% | -1,513.18% | -884.14% |
| Earnings before Tax (EBT) 1 | -9.533 | -14.4 | -19.13 | -19.44 | -28.96 | -22.4 | -25.62 | -34.69 |
| Net income 1 | -9.533 | -14.4 | -19.13 | -19.44 | -28.96 | -22.4 | -25.62 | -34.69 |
| Net margin | -6,809.29% | -8,834.36% | -14,168.15% | -13,790.78% | -14,337.62% | -12,985.51% | -1,439.44% | -908.06% |
| EPS 2 | -2.620 | -0.4500 | -0.4000 | -0.4000 | -0.6000 | -0.4400 | -0.4550 | -0.5500 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/31/21 | 3/31/22 | 3/31/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.05 | 0.033 | 0.03 | 0.021 | 0.056 | 0.049 | 0.042 | 0.046 | 0.065 | 0.04 | - | - | 0.1 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -5.666 | -3.152 | -4.695 | -6.521 | -5.556 | -4.295 | -5.461 | -8.157 | -14 | -5.734 | -6.108 | -5.982 | -6.108 | -5.6 | -5.6 |
| Operating Margin | -11,332% | -9,551.52% | -15,650% | -31,052.38% | -9,921.43% | -8,765.31% | -13,002.38% | -17,732.61% | -21,544.62% | -14,335% | - | - | -6,107.5% | - | - |
| Earnings before Tax (EBT) 1 | -5.846 | -3.82 | -4.851 | -6.385 | -4.389 | -3.661 | -4.909 | -7.816 | -12.58 | -5.817 | -5.5 | -5.5 | -5.5 | -5.6 | -5.6 |
| Net income 1 | -5.846 | -3.82 | -4.851 | -6.385 | -4.389 | -3.661 | -4.909 | -7.816 | -12.58 | -5.817 | -5.5 | -5.5 | -5.5 | -5.6 | -5.6 |
| Net margin | -11,692% | -11,575.76% | -16,170% | -30,404.76% | -7,837.5% | -7,471.43% | -11,688.1% | -16,991.3% | -19,347.69% | -14,542.5% | - | - | -5,500% | - | - |
| EPS 2 | -0.1200 | -0.0800 | -0.1000 | -0.1300 | -0.0900 | -0.0800 | -0.1000 | -0.1600 | -0.2600 | -0.1200 | -0.1100 | -0.1100 | -0.1100 | -0.1100 | -0.1100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/31/22 | 5/13/22 | 8/15/22 | 11/14/22 | 3/31/23 | 5/15/23 | 8/14/23 | 11/14/23 | 4/1/24 | 5/15/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 1.240 | 1.450 | 1.190 | 0.8000 | - | -0.2200 | -0.6500 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.07 | 0.02 | - | - | - | 1.2 | 2.3 | - |
| Capex / Sales | 48.57% | 13.5% | - | - | - | 695.65% | 129.21% | - |
| Announcement Date | 3/30/20 | 3/31/21 | 3/31/22 | 3/31/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.362
USD
Average target price
3.583
USD
Spread / Average Target
+889.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.71% | 18.56M | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -1.37% | 21.96B | |
| -6.96% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B | |
| +77.64% | 8.87B |
- Stock Market
- Equities
- AIM Stock
- Financials AIM ImmunoTech Inc.
